Tag: Enhertu
Trastuzumab Deruxtecan Offers an Effective Treatment Option for Patients with Difficult-to-treat...
Trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca; previously known as DS-8201a) is an effective treatment option for patients diagnosed with difficult-to-treat HER2-expressing solid tumors.
World ADC 2023 London – What to Expect
With renewed focus and commitment in creating a platform for innovative scientific insights and transformative experiences, 13th World ADC in London, held March 13...
Sacituzumab Govitecan Expected to Become Gilead’s Blockbuster Following Expanded Approval
In early February this year, the U.S. Food and Drug Administration (FDA) approved sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with...
Trastuzumab Deruxtecan Demonstrates Clinical Activity in Neoadjuvant Setting in Patients with...
Patients diagnosed with hormone receptor-positive (HR+)/HER2-negative breast cancer frequently experience disease response to neoadjuvant therapy. However, following standard chemotherapy or endocrine therapy, even in combination with CDK4/6...
Trastuzumab Deruxtecan Shows Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously...
Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...
Gilles Gallant, BPharm, PhD, FOPQ, Receives the 2022 George R. Pettit...
Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer, at Mythic Therapeutics has received the George R. Pettit Individual Input to the Field Award for 2022. The award was presented at the 13th World ADC Conference, held in San Diego, CA, during the 9th World ADC Awards Ceremony held on Thursday, September 8, 2022.
US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC
The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...
Trastuzumab deruxtecan Doubles Progression-Free Survival in Metastatic Breast Cancer with Low...
The use of trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca), a new HER2-targeting antibody-drug conjugate, doubled progression-free survival (PFS) compared to standard-of-care treatment with...
FDA Approves Trastuzumab Deruxtecan for Adult Patients with Unresectable or Metastatic...
The U.S. Food and Drug Administration (FDA) has approved fam-trastuzumab deruxtecan-nxki (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with unresectable or metastatic HER2...
The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
